Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.85 |
| ▸ | HRH1 | P35367 | 4/20 | 0.56 |
| ▸ | HRH2 | P25021 | 3/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CCR3 | P51677 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4237843 | 0.92 | HRH3 (0.72) | HRH3HRH1HRH2SIGMAR1 | |
| SCHEMBL5206619 | 0.92 | HRH3 (1.00) | HRH3HRH1HRH2SIGMAR1MAOA | |
| SCHEMBL5208517 | 0.87 | HRH3 (1.00) | HRH3HRH1HRH2SIGMAR1MAOA | |
| SCHEMBL4238055 | 0.83 | HRH3 (0.58) | HRH3SIGMAR1MAOAMAOB | |
| SCHEMBL1891613 | 0.82 | HRH3 (0.57) | HRH3MAOAMAOB | |
| SCHEMBL4240823 | 0.81 | HRH3 (0.57) | HRH3HRH1HRH2SIGMAR1MEN1 | |
| SCHEMBL4228461 | 0.81 | HRH3 (0.57) | HRH3HRH1HRH2SIGMAR1MAOA | |
| SCHEMBL4231975 | 0.81 | HRH3 (0.57) | HRH3HRH1HRH2MAOAMAOB | |
| SCHEMBL229024 | 0.81 | HRH3 (1.00) | HRH3HRH1HRH2MAOAMAOB | |
| SCHEMBL4232384 | 0.80 | HRH3 (0.56) | HRH3HRH1MAOAMAOBCCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | HRH3 210/4885HRH1 217/4885HRH2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.